1. Academic Validation
  2. M2 Macrophage exosomal HOXC13-AS in laryngeal cancer immunity via targeting miR-485-5p/IGF2BP2/PD-L1

M2 Macrophage exosomal HOXC13-AS in laryngeal cancer immunity via targeting miR-485-5p/IGF2BP2/PD-L1

  • Int Immunopharmacol. 2024 Oct 25:140:112742. doi: 10.1016/j.intimp.2024.112742.
Shizhi He 1 Yurong He 1 Siyu Zhu 1 Ru Wang 1 Shaokun Liu 1 Lingwa Wang 1 Xixi Shen 1 Xinyu Li 1 Shaoshi Chen 1 Jugao Fang 2
Affiliations

Affiliations

  • 1 Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University. Dongcheng District, Beijing, China; Key Laboratory of Otorhinolaryngology Head and Neck Surgery (Capital Medical University), Ministry of Education. Dongcheng District, Beijing, China.
  • 2 Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University. Dongcheng District, Beijing, China; Key Laboratory of Otorhinolaryngology Head and Neck Surgery (Capital Medical University), Ministry of Education. Dongcheng District, Beijing, China. Electronic address: fangjugao2@ccmu.edu.cn.
Abstract

This study investigates the role of M2-exo-mediated HOXC13-AS in laryngeal squamous cell carcinoma (LSCC) by examining its transmission to tumor microenvironment (TME) macrophages. Exosomes from M2 macrophages were isolated and characterized using transmission electron microscopy, nanoparticle tracer analysis and western blot. Expression of HOXC13-AS, miR-485-5p, IGF2BP2, and PD-L1 was analyzed. Different interventions on LSCC cell function and immune escape were detected using molecular biological techniques. The study found that elevated HOXC13-AS were present in LSCC, and M2-exo expression was significantly increased in LSCC cells. Silencing HOXC13-AS in M2-exo inhibited LSCC malignant progression and immune escape in vivo and in vitro. M2-exo-mediated HOXC13-AS also regulated IGF2BP2 expression, impacting cellular biological function and immune escape process. The study concludes that M2-exo-mediated HOXC13-AS promotes LSCC malignancy and immune escape.

Keywords

HOXC13-AS; Immune escape; LSCC; M2-exo; PD-L1.

Figures
Products
Inhibitors & Agonists
Other Products